Goldman Sachs Group started coverage on shares of IDEXX Laboratories (NASDAQ:IDXX) in a research note issued to investors on Monday morning, BenzingaRatingsTable reports. The firm issued a neutral rating and a $277.00 price target on the stock.

Several other research firms have also recently commented on IDXX. Bank of America set a $300.00 target price on shares of IDEXX Laboratories and gave the stock a buy rating in a research note on Friday, June 21st. Stifel Nicolaus raised their target price on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a buy rating in a research note on Monday, July 22nd. Credit Suisse Group raised their target price on shares of IDEXX Laboratories from $282.00 to $293.00 and gave the stock an outperform rating in a research note on Friday, August 16th. BidaskClub upgraded shares of IDEXX Laboratories from a buy rating to a strong-buy rating in a research note on Wednesday, August 28th. Finally, Canaccord Genuity restated a buy rating and issued a $285.00 target price on shares of IDEXX Laboratories in a research note on Friday, August 2nd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. IDEXX Laboratories has a consensus rating of Buy and a consensus price target of $285.29.

IDXX stock opened at $270.99 on Monday. IDEXX Laboratories has a one year low of $176.11 and a one year high of $292.17. The stock has a market capitalization of $23.00 billion, a PE ratio of 63.61 and a beta of 0.85. The company has a debt-to-equity ratio of 4.49, a quick ratio of 0.83 and a current ratio of 1.15. The company has a fifty day moving average of $279.08 and a 200-day moving average of $252.99.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, August 1st. The company reported $1.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.06. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The company had revenue of $620.10 million during the quarter, compared to analysts’ expectations of $627.10 million. During the same quarter last year, the business earned $1.23 EPS. The business’s revenue was up 6.8% on a year-over-year basis. Equities analysts forecast that IDEXX Laboratories will post 4.86 earnings per share for the current fiscal year.

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 9,044 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $263.86, for a total transaction of $2,386,349.84. Following the completion of the transaction, the director now directly owns 12,116 shares in the company, valued at approximately $3,196,927.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rebecca M. Henderson sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $271.17, for a total transaction of $1,084,680.00. Following the transaction, the director now owns 14,696 shares of the company’s stock, valued at $3,985,114.32. The disclosure for this sale can be found here. Insiders sold a total of 73,305 shares of company stock valued at $19,402,442 in the last quarter. Insiders own 2.70% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Altshuler Shaham Ltd acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $28,000. Cornerstone Advisors Inc. boosted its stake in shares of IDEXX Laboratories by 100.0% during the 2nd quarter. Cornerstone Advisors Inc. now owns 140 shares of the company’s stock worth $39,000 after purchasing an additional 70 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of IDEXX Laboratories by 32.5% during the 2nd quarter. Captrust Financial Advisors now owns 151 shares of the company’s stock worth $42,000 after purchasing an additional 37 shares during the last quarter. Monetary Management Group Inc. acquired a new stake in shares of IDEXX Laboratories during the 1st quarter worth about $45,000. Finally, Personal Wealth Partners acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $52,000. Hedge funds and other institutional investors own 87.04% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Further Reading: What causes a yield curve to invert?

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.